Binding of human polymeric IgA ligand to its epithelial cell polymeric Ig receptor, pIgR, has been shown to stimulate pIgR apical transcytosis in an in vitro system, based on polarized confluent MDCK cells expressing rabbit pIgR. The present study aimed at testing whether such a stimulation also occurs in vivo. Transcytosis of pIgR was monitored by rat liver output of total secretory component (SC) into bile, measured by radial immunodiffusion as the sum of free SC and pIgAbound SC. Whereas in the perfused rat liver system addition of pIgA to the perfusate showed no effect, i.v. injection of human and rat pIgA, but not of monomeric IgA nor PBS, in living rats significantly increased total bile SC output for more than 1 h. Furthermore, depletion of the normal pIgA level circulating in the liver before injecting more pIgA was not required to show the stimulation. Our data thus strongly suggest that stimulation of liver pIgR transcytosis by pIgA ligand binding is physiologically relevant, helping to quickly adjust pIgA transport into bile to increase circulating pIgA levels, without need for increased SC/pIgR synthesis.
Introduction
IgA, the principal Ig in secretions and the first specific defence against external antigens (1, 2) , is mainly dimeric (dIgA), with some larger forms of polymeric IgA (pIgA). Synthesized by plasmacytes in the mucosal lamina propria, pIgA is transported into secretions by the polymeric Ig receptor (pIgR), the transmembrane glycoprotein made by many epithelial cells lining mucoglandular surfaces (3) . After passing through the Golgi, the pIgR is directed to the basolateral surface, where it can bind available pIgA. Then, pIgR, with or without bound ligand, is internalized and transcytosed to the apical surface. There, the extracellular part of pIgR [called the secretory component (SC)] is cleaved off and released, either bound to pIgA, forming secretory IgA (S-IgA), or in free form [free secretory component (FSC)] (4-6). Three steps were described in pIgR transcytosis (7) . First, pIgR is internalized from the basolateral surface, in clathrin-coated pits, and enters basolateral endosomes. Second, there is a microtubule-dependent passage from basolateral early endosomes to apical recycling endosomes. Third, pIgR is transported from apical endosomes to the apical cell surface and proteolytically cleaved.
After pIgR internalization, which requires phosphorylation of Tyr668, Tyr734 and Ser726 in its intracytoplasmic domain (8, 9) , transcytosis is regulated at multiple levels. Constitutive (ligand-free) pIgR transcytosis is stimulated by phosphorylation of Ser664, in the first 17 intracytoplasmic amino acids, forming the 'basolateral signal' directing pIgR from the Golgi to the basolateral membrane (10) . Binding of dIgA ligand to basolateral pIgR further stimulates pIgR transcytosis (11, 12) . Phosphorylation of Ser664 is not required for this effect which still occurs using a mutated pIgR (Ser664Ala). Stimulation of pIgR transcytosis by pIgA binding occurs during the third step of transcytosis (7) .
Stimulation of pIgR transcytosis by pIgA was demonstrated using polarized Madin-Darby canine kidney (MDCK) cells stably transfected with rabbit pIgR as confluent monolayers, and human dIgA as ligand, a heterogenous in vitro system (12) . We therefore decided to test whether stimulation of pIgR transcytosis by pIgA similarly occurs in vivo. Rat liver is a convenient in vivo model to study pIgR transcytosis in bile. (i) In contrast to human liver, rat liver actively transports pIgA from blood into bile via hepatocyte SC/pIgR (13) . (ii) Bile flow in rats is important (15-20 ml/24 h/250 g) and bile contains large amounts of free (FSC) and pIgA-bound SC (BSC) (14) . (iii) Rat bile, easy to collect by cannulation, contains less mucins, bacteria and proteases than other secretions. The effect of an increase in circulating pIgA on rat pIgR transcytosis into bile was first tested in perfused rat livers and later in living rats. Human dIgA was mainly used, because of its availability, and results were extended to rat pIgA to achieve a fully homologous system. No stimulatory effect was found using perfused livers, but in living rats, stimulation of biliary pIgR transcytosis was found with both human and rat pIgA, but not with monomeric IgA, strongly suggesting that this effect could be of physiological relevance.
Methods

Animals
Sprague-Dawley male rats (220-250 g; Charles River, St Aubin-Les-Elbeuf, France) were used for liver perfusions, and Wistar rats (animal house, UCL Medical Faculty) for living animals. Protocols of experiments agreed with rules of the Animal Ethics Committee of the UCL Medical Faculty, Brussels.
Bile collection
To initiate liver perfusions, rats were anesthetized with Nembutal (Abbott, North Chicago, IL) at 100 µl/100 g body weight i.p. or with ether. The bile duct was cannulated before liver perfusion (15) . Bile was collected at 15 min intervals for 180 or 240 min, in preweighed tubes for determination of bile flow. Before storage, 5 µl of anti-protease mixture (40 mM iodoacetamide, 40 mM benzamidine, 80 mM EDTA, 0.6 M azide and 2 mg/ml soybean trypsin inhibitor) and 2 µl of phenylmethylsulfonyl fluoride (350 mg/100 ml anhydrous isopropanol) were added to each 15 min sample.
Liver perfusion
After anesthesia and bile duct cannulation, rat livers were perfused in situ in closed circuit, as described (16) , at a flow rate of 6-7 ml/min for 180 min. The perfusion medium (40 ml), kept oxygenated at 37°C, was composed of Krebs-Ringer bicarbonate, pH 7.4, containing 3% (w/v) BSA (Fraction V; Sigma), washed fresh bovine erythrocytes to 27% hematocrit and a 4 times higher level of amino acids than that in normal plasma.
Injected FSC and IgA solutions
Human dIgA and monomeric IgA (mIgA) were purified from IgA1κ (Gera) myeloma serum (17) , rat pIgA (75% dIgA) from rat hybridoma LO-DNP-64 ascites (18) and FSC from rat bile (19) respectively. For perfusions, human dIgA was added into the medium to obtain 100 µg/ml. For in vivo transcytosis assays, proteins were always injected into a tail vein in 0.5 ml of PBS. For control i.v. injections, proteins were replaced by 0.5 ml of PBS. 
Quantitation of proteins in rat bile
FSC, rat and human IgA were quantitated by radial immunodiffusion (20) . Goat anti-rat FSC antiserum was absorbed on rat S-IgA-Sepharose, to precipitate only FSC (21) . Rat and human IgA were quantitated with H chain-specific antisera against rat or human IgA, absorbed on human or rat IgA-Sepharose respectively to avoid cross-reactions. Standard rat S-IgA (mostly dimeric) was purified from rat bile (19) . Standard human dIgA1 was mixed with an excess of rat FSC to obtain chimeric S-IgA (rat FSC bound to human dIgA). Total level of BSC was the sum of levels of rat and human IgA, multiplied by 0.193 to obtain BSC, which represents 19.3% of the mass of dimeric human and rat S-IgA (80 versus 415 kDa). All human dIgA in bile was bound to rat SC, as shown by its increase in size on polyacrylamide gel electrophoresis without SDS when compared with the injected dIgA (not shown). Total rat SC output in bile was obtained by summing up FSC and BSC outputs, and was finally used as measurement of rat liver pIgR transcytosis. Protein amounts were given in pmol, taking the mol. wt of S-IgA as 415,000 and of BSC and FSC as 80,000.
Results
Experiments with the perfused rat liver system
The original in vitro demonstration of pIgA-induced stimulation of pIgR transcytosis (12) compared apical SC release of pIgR-transfected MDCK cells that were exposed or not to pIgA on the basolateral side. To achieve similar initial conditions, i.e. hepatocytes not exposed to circulating pIgA, we perfused livers with pIgA-free medium, which is reported to induce a strong decrease of S-IgA, but not of FSC, in bile (22) . Then, a pIgA bolus was added to the medium to test for stimulation of pIgR transcytosis in bile, evidenced by comparing total SC output in bile before and after addition of pIgA. As a control perfusion, the bile duct was cannulated and the liver was perfused with pIgA-free medium. FSC and rat S-IgA (BSC) were assayed in the successive bile fractions. As expected, S-IgA (or BSC) output rapidly decreased with time, but remained measurable at small levels until the end of perfusion Fig. 1 . Output of rat S-IgA (A) and FSC (B) in bile of living rats injected with 2 mg of rat FSC at time 0, followed after 120 min by 5 mg of human dIgA (j, nϭ4) or PBS (s,nϭ3). Control rats were injected at time 0 with PBS in place of the 2 mg of FSC, and bile was collected only during 120 min (u, nϭ3). Each value is the mean Ϯ SEM.
(data not shown). Bile flow and FSC output also decreased rapidly after the perfusion start, compared with the same parameters in living rats ( Table 1 ). The decrease of bile flow was not surprising because the medium lacked bile acids, which strongly contribute to bile flow (23) . However, the decrease in FSC output suggested that the conditions of perfusion were not optimal.
Nevertheless, two series of perfusions were started, with the hope of detecting an effect before biliary secretion would deteriorate. In the first series of experiments, 4 mg of human dIgA were added to the medium immediately after the start of the perfusion and, in the second, 30 min later. Total bile SC output in these two series of perfusions displayed no significant difference with that of IgA-free perfusions (data not shown). No stimulation of pIgR transcytosis due to human pIgA could be demonstrated. It was concluded that the present perfusate composition was inappropriate for testing rat liver pIgR transcytosis and it was decided to use bile duct-cannulated living rats.
Experiments on living rats
It was still assumed preferable to first reach a 'basal period' with no or little circulating pIgA and only constitutive bile SC/ pIgR transcytosis, before injecting dIgA to test for stimulation. We had observed earlier that injection of 2 mg of rat FSC to rats induced an 80% drop of S-IgA level in bile within 2 h (15). The injected FSC was assumed to convert all circulating pIgA into S-IgA, artificially lowering the level of circulating pIgA for a certain time. Therefore, after bile duct cannulation, 2 mg of rat FSC was injected (ϭ time 0) and bile collection started immediately thereafter. Two hours later, 5 mg of human dIgA was injected and bile collection extended for an additional 2 h. Upon FSC injection, bile S-IgA output decreased for up to 120-135 min, as expected (15) . PBS injection at time 0 unexpectedly produced a major increase of S-IgA output for 120 min (Fig. 1A) . In contrast, after subsequent injection of 5 mg of human dIgA at 120 min, rat S-IgA output increased, compared to that of rats injected at 120 min with PBS (Fig. 1A) . To our surprise, bile FSC output also strongly increased, peaking at 90-120 min after FSC injection at time 0. Control rats receiving PBS instead of FSC at time 0 similarly displayed a strong increase in FSC output (Fig. 1B) . After subsequent injection of human dIgA at 120 min, bile FSC output progressively decreased (Fig. 1B) , whereas a drop, followed by a new increase in FSC output was observed in similar FSC preinjected rats after PBS injection at 120 min (Fig. 1B) . However, after injection of human dIgA at 120 min, total FSC output showed a strong increase, both when compared to that before dIgA injection (150%) and to that of rats injected with PBS instead of dIgA (300%) [significant (PϽ0.05) between 135 and 210 min] (Fig. 2) . This result already strongly suggested that human dIgA could stimulate in vivo rat liver total SC output, representing pIgR transcytosis.
In two further series of experiments, we assessed if the 'basal period' with low plasma pIgA could be omitted before the injection of human dIgA, allowing for even more natural conditions. After bile duct cannulation for 60 min, 5 mg of human dIgA, rat dIgA, or human mIgA, or PBS were injected, and bile was further collected for 240 min. Figure 3(A) shows that the output of rat S-IgA was roughly similar when rats were injected with human dIgA, mIgA or PBS, compared to rats injected with rat pIgA which, as expected, secreted a large amount of rat S-IgA. A rather small increase in rat SIgA output, between 75 and 135 min, was nevertheless observed for rats injected with PBS or mIgA, comparable in size to that observed in Fig. 2(A) , taking into account the different scales. The bile output of FSC (Fig. 3B ) decreased in rats injected with rat or human dIgA, but increased in rats injected with PBS or mIgA. A similar increase in FSC output was already noted in rats injected at time 0 with PBS or FSC (Fig. 1B) . Total bile SC output was again strongly increased after injection of human dIgA when compared both to that before dIgA injection and to that of control PBS-and mIgAinjected rats (220%) [significant (PϽ0.05) between 75 and 135 min] (Fig. 4) , clearly indicating that the 'basal period' was not necessary to show pIgR transcytosis stimulation.
In our final series of experiments, where human dIgA was replaced by an equal amount of rat pIgA, total bile SC output was similarly significantly increased (200%) (PϽ0.05 between 60 and 135 min) when compared to rats injected with PBS or mIgA (Fig. 4) . This experiment with a most simple and homologous system further supports that stimulation of rat liver pIgR transcytosis by an increased plasma level of pIgA could be physiologically relevant.
Discussion
Hepatic pIgR transcytosis was quantitated by radial immunodiffusion in rat bile, summing up levels of FSC and rat and/or human pIgA-BSC. For FSC, it was checked that the addition of even a 50-fold excess of S-IgA (or BSC) did not modify the FSC value obtained (unpublished data); hence, quantitation of FSC seems adequate. IgA titrations were used for measuring levels of BSC, assuming that all IgA in rat bile, whether rat or human, would be S-IgA. In fact, traces of rat monomeric IgA, not bound to SC, also occur in rat bile, but are thought to be irrelevant with regard to the total IgA in rat bile (14) . In addition, the rat S-IgA standard used was mostly dIgA, with some larger sizes. Rat bile also contains significant amounts of S-IgA trimers and tetramers (19, 24) . The size of IgA influences its assay by radial immunodiffusion (25) . The use of mostly dimeric rat S-IgA as standard could thus lead to an underestimation of total rat S-IgA in bile. However, given that there is only one molecule of SC per rat S-IgA dimer, trimer or tetramer (24) , the conversion factor used, i.e. 0.193 (see Methods), overestimates the SC content of S-IgA trimers and tetramers, in which SC is a smaller part of the whole molecule (i.e. 0.139 and 0.109 respectively). We believe that these error factors more or less compensate for each other. In addition, this problem was non-existent for human dIgA, itself used to make the standard human dimeric S-IgA. Moreover, in the present experiments, SC bound to endogenous rat pIgA was usually a minor fraction of total SC; rat FSC and SC bound to injected human dIgA and rat pIgA were the major sources.
To test for stimulation of pIgR transcytosis by pIgA under more physiological conditions than the original in vitro system (12), bile duct-cannulated rat livers were first perfused with pIgA-free medium, to abolish pIgR ligand stimulation; then pIgA was added to the medium to allow for a possible stimulation of bile pIgR/SC transcytosis. Perfusions without pIgA confirmed that rat S-IgA (or BSC) output rapidly decreased, as expected (22), but did not stop, remaining at a small level until the end. This is probably due to the known occurrence of IgA-secreting cells in rat liver (26) . However, the perfused liver was unable to maintain its normal bile flow and normal output of SC (Table 1) . One reason may be found in the composition of the medium, which probably lacked essential constituents, including bile acids, for bile secretion (23) . Notwithstanding, two series of perfusions were performed without waiting Ͼ30 min to add pIgA, to be as close as possible to original in vivo conditions. Addition of human dIgA directly at the start of perfusion, or 30 min later, induced no detectable increase in total SC output, compared to that without dIgA. In these experiments, bile FSC output appeared as a limiting factor; when human dIgA was transported into bile, bile FSC output almost disappeared (not shown). Moreover, mean bile recovery of human dIgA during the 3 h perfusions was only 7.3% of the injected amount (not shown), as compared to 40-60% in living rats (15) . For all these reasons, it was decided to move to bile duct-cannulated living rats, to be used first after an i.v. FSC injection. Fig. 4 . Total SC output (transcytosis of pIgR) in bile of living rats injected with 5 mg of human dIgA (j,nϭ4), 5 mg of rat pIgA (m,nϭ4), PBS (s,nϭ3) or 5 mg of mIgA (u,nϭ3) after 60 min of bile collection. Each value is the mean Ϯ SEM. *Significant differences (PϽ0.05) between rats injected with human dIgA and rats injected with PBS, by unpaired t-test.°Significant differences (PϽ0.05) between rats injected with rat pIgA and rats injected with PBS, by unpaired t-test. # Significant differences (PϽ0.05) between rats injected with human dIgA and rats injected with human mIgA, by unpaired t-test.
The drop in rat S-IgA biliary output after FSC injection (Fig. 1A) confirmed our previous observation (15) and can be attributed to the transient drop in circulating pIgA. Indeed, injected FSC is expected to bind rapidly to serum pIgA, yielding circulating S-IgA which can no longer bind pIgR and therefore cannot be secreted into bile, as previously shown (15) . When human dIgA was injected into such rats, rat biliary S-IgA output unexpectedly rose again, when compared to similar rats injected with PBS instead of human dIgA (Fig. 1A) . Presumably, the large amount of injected human dIgA rapidly binds remaining circulating rat FSC, allowing new rat pIgA, continuously arriving into plasma from the thoracic duct lymph (27) , to be secreted into bile via pIgR transcytosis.
Curiously, bile FSC output increased~3-fold within 2 h after FSC injection (Fig. 1B) . Although the fate of i.v. FSC is not known, we do not think that i.v. FSC, at least that fraction remaining unbound to serum pIgA, would be transported significantly into bile. A small amount of rat FSC, transported into bile by a putative fluid-phase transcytosis after i.v. injection, would be largely unable to explain the large (3-fold) increase in FSC output observed. Indeed, fluid-phase transcytosis of BSA, another serum protein of similar size, was only 0.8% of the injected dose (60 µg) (28) . Looking for another explanation, we observed that rats injected with the same volume (0.5 ml) of PBS (Fig. 1B) or mIgA in the same volume of PBS (Fig. 3B) displayed the same large increase in bile FSC output, along with some increase in bile flow (not shown) and in rat S-IgA output ( Figs 1A and 3A) . This was reproduced with endotoxin-free sterile PBS (not shown) instead of the usual filtered (0.2 µm) PBS, excluding possible effects of bacterial lipopolysaccharide. Hemodynamic changes, perhaps induced by the large volume injected within a limited time (0.5 ml within~0.5-1.0 min, for a rat plasma volume of 6-8 ml), might play a role in these effects, but this should be formally demonstrated and is irrelevant to the present investigation.
When human dIgA was injected into FSC-preinjected rats, the FSC output decreased (Fig. 1B) , perhaps due to the large increase in circulating pIgA available for pIgR transport, but never decreased below the initial FSC output. This indicates that pIgR/SC transcytosis was not saturated and that FSC was not limiting, as it seemed during liver perfusions. Noteworthy, the large increase in FSC output observed after FSCinjection at time 0 did not prevent a subsequent PBS injection from inducing again a new rise in FSC output (Fig. 1B) . Total bile SC output, our measure of liver pIgR transcytosis, significantly increased for some time after injection of human dIgA, but not of PBS, in FSC-preinjected rats (Fig. 2) , supporting the previous in vitro data (12) .
A 'basal period' with low circulating pIgA was not required to show pIgA-induced stimulation of pIgR transcytosis. When FSC injections were omitted, injected human dIgA also stimulated total liver SC output. As control, mIgA was used because its structure is similar to that of injected pIgA; however, mIgA, like IgG, is not transcytosed across hepatocytes. This control did not stimulate total SC output, underlining the specificity of pIgA-induced stimulation of pIgR transcytosis (Fig. 4) . During this, recovery of human dIgA in rat bile for 3 h was 55-60% (not shown), entirely comparable to previous data (13, 15) . Finally, homologous rat pIgA was also stimulating total SC output in bile, approaching still more the normal physiological situation. Recovery of rat pIgA in bile, when calculated for 180 min by subtracting in Fig. 3(A) the amount of rat S-IgA measured in bile after human dIgA injection from that after rat pIgA injection, also amounted to 47% of the injected amount, still in complete agreement with reported data (13, 15) .
The pIgA-induced stimulation of SC/pIgR transcytosis, first described in in vitro cell culture systems, was suggested to adjust pIgR transcytosis to various loads of pIgA, to ensure that an increase in local pIgA antibody levels would rapidly lead to their increased transport in local secretion, in order to adequately perform their protective function (12) . Our data confirm that in living adult rats, with a mild stimulation of rat liver pIgR transcytosis by the relatively low plasma pIgA level, an increase in circulating pIgA will quickly increase pIgR and pIgA transcytosis into bile, without any need for increased pIgR synthesis. The latter would indeed require time, as shown by experiments using cytokines (IFN-γ, tumor necrosis factor-α, IL-4) to increase pIgR mRNA and protein in epithelial cell lines. In these experiments, 6-12 h were required to detect a positive effect on SC production (29) (30) (31) . Moreover, a significantly increased output of total bile SC was already observable at 15 min after pIgA injection, excluding new synthesis of pIgR/SC, because experiments with radiolabeled precursors have shown that 35-40 min is required to move pIgR/SC from its site of synthesis to its site of discharge into the bile in rat liver (32) . The stimulation of pIgR transcytosis occurs during the third step of transcytosis (delivery from the apical recycling endosomes to the apical surface) (7). pIgR transcytosis stimulation by dIgA could be mediated by second messenger pathways. Indeed, dIgA binding to the pIgR causes activation of protein kinase C (PKC) and release of inositol 1,4,5-triphosphate (IP 3 ). That, in turn, increases the intracellular Ca 2ϩ concentration. The IP 3 -sensitive pool of Ca 2ϩ may reside primarily in organelles in the apical region of the cytoplasm. The PKC activation and increase in intracellular Ca 2ϩ could thus regulate membrane traffic in the apical region of the cells (33) .
